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Abstract
The γ-aminobutyric acid (GABA) transporter 1 (GAT1) belongs to a family of Na+ and Cl−-coupled transport proteins and pos-
sesses 12 putative transmembrane domains. To perform structural analyses of the GAT1 protein, the GAT1/green fluorescent pro-
tein (GFP) fusion protein was functionally expressed in insect Sf9 cells by the BAC-TO-BAC® baculovirus expression system. A
two-step procedure to purify the GAT1/GFP fusion protein from insect Sf9 cells has been established and involves immunoaffinity
chromatography using self-prepared anti-GFP antibodies and size-exclusion fast protein liquid chromatography (SE-FPLC). A yield
of 200–300 μg of the GAT1/GFP protein could be purified from 400–600 mL of infected Sf9 cells. The purified protein was
analyzed by transmission electron microscopy (TEM), which revealed that the GAT1/GFP fusion protein was isolated in its
monomeric form.
Introduction
γ-Aminobutyric acid (GABA) is the most abundant inhibitory
neurotransmitter in the central nervous system (CNS) of verte-
brate species. GABAergic neurotransmission is efficiently
terminated through the quick removal of GABA from the
synaptic cleft by GABA transporters (GATs). The activities of
GATs are important for controlling the concentration and dwell
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time of GABA in the synaptic cleft and tightly regulating the
synaptic inhibition of the GABA receptor [1]. GATs, which are
located in the plasma membranes of neurons and glia cells,
belong to the solute carrier 6 (SLC6) family in mammals, which
is subdivided into four groups based on sequence composition:
GATs, GABA, osmolyte and creatine transporters, neurotrans-
mitter amino acid, monoamine and nutrient amino acid/orphan
transporters [2,3]. Four subtypes of GATs (GAT1–4) have been
identified thus far [4].
GAT1, the first neurotransmitter transporter to be cloned, is
abundantly but restrictively expressed throughout rat, mouse,
and human CNSs [4-8]. The transmembrane (TM) topology of
GAT1 demonstrates that this single polypeptide contains twelve
TM domains connected by hydrophilic loops with the amino
and carboxy-termini residing in the cytoplasm [9,10]. Addition-
ally, the GAT1 protein contains three conserved N-glycosyla-
tion sites [9]. The role of N-linked glycans in the GABA uptake
activity of GAT1 has been extensively clarified [11,12]. The
topological model of GAT1 is in agreement with the high-reso-
lution crystal structure of LeuTAa, a homologue of the SLC/
neurotransmitter sodium symporter (NSS) transporters from the
bacterium Aquifexaeolicus [13]. The LeuTAa structure has pro-
vided a good model for the study of GAT1 and other SLC6
members [3]. The activities of GATs are driven by electrochem-
ical gradients of Na+ and Cl− ions [14], and the binding pocket
for the substrate and two sodium ions has been clearly docu-
mented in the crystal structure of LeuTAa. The chloride depen-
dence has also been elucidated by identifying crucial structural
elements for chloride binding [15,16]. In addition, a similar core
architecture was observed based on several crystal structures of
sodium symporters from different families; this observation
strongly supports an alternating access mechanism as a common
transport mechanism for the GAT1 protein [13,17-20].
Since the GABAergic system has been implicated in many
nervous system diseases [21-24], the regulation of GABA activ-
ity is of considerable medical interest [25,26] and the predomi-
nant GABAergic nerve ending protein, GAT1, is a potential
drug target. The exact three-dimensional structure of GAT1
protein could provide more information for pharmaceutical
research.
The structural analysis of most membrane proteins is chal-
lenging since significant protein yields are required and because
eukaryotic membrane proteins should be in a native and func-
tional conformation during expression and purification. The
natural abundance of most membrane proteins is typically not
high enough for the isolation of sufficient quantities for func-
tional and structural studies. In this work, the baculovirus
expression system was selected for GAT1 protein expression.
Mass spectrometry, gel electrophoresis and GABA uptake
assays were employed to characterize the product during
expression and purification. In our work, the GAT1 protein with
a green fluorescent protein (GFP) tag at its C-terminus, which
does not affect the relevant functions of GAT1 [27], could be
purified in a functional form. In addition, the GFP tag has
several advantages for further work. For example, it provides a
powerful means for affinity purification with specific anti-GFP
antibodies that have already been produced, generates green
fluorescence for the efficient observation of the expression of
the protein of interest, and has a known crystal structure [28,29]
for future structural studies.
Results and Discussion
Expression and characterization of the GAT1/
GFP fusion protein in insect cells
Construction and analysis of the GAT1/GFP recom-
binant baculovirus
The purification of a protein of interest for structural studies
requires an abundant source of the protein from heterologous
overexpression. In our work, Escherichia coli was not a suit-
able system for the expression of the GAT1/GFP recombinant
protein due to its twelve TM domains and N-glycosylation
status. After 30 years of development, the baculovirus expres-
sion system has become a widely applied technology for pro-
ducing recombinant proteins [30,31]. Since the production of
adequate quantities of a homogenous protein is a rate-limiting
step, in this study, we chose the baculovirus expression system
for GAT1 protein expression instead of the mammalian cell
expression system.
The GAT1/GFP recombinant cDNA was cloned into the
pFastBac1 vector (Figure S1A, Supporting Information File 1)
and prepared in bacmids (Figure S1B, Supporting Information
File 1) for the baculovirus expression system. GAT1/GFP
recombinant proteins were expressed in Sf9 cells by viral infec-
tion for 72 h. The expression of the GAT1/GFP protein was
further characterized. After 72 h post-infection, Sf9 cells with
green fluorescence were controlled by flow cytometry
(Figure 1A) and analyzed by fluorescence microscopy
(Figure 1B). The expression of GAT1/GFP in insect cells was
further determined by sodium dodecyl sulfate polyacrylamide
gel electrophoresis SDS-PAGE, followed by Western blotting
with either anti-GFP pAb (Figure 1C) or anti-GAT1 pAb
(Figure 1D) and silver staining (Figure 1E) after immunoprecip-
itation with anti-GFP mAb (showing the band at approximately
50 kDa). In infected Sf9 cells, the GAT1/GFP-fusion protein
shows two main bands in SDS-PAGE (7.5%) (indicated by
arrows), and the monomeric form appears as a main band of
approximately 75 kDa. This band can bind strongly only with
Galanthusnivalis agglutinin (GNA, digoxigenin-conjugated
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Figure 1: Expression of GFP-tagged GAT1 in infected insect cells. (A) Flow cytometry analysis of GAT1/GFP in Sf9 cells. (B) Fluorescence microsco-
py of infected Sf9 cells. The GFP fluorescence in the GAT1/GFP fusion protein was detected. The solubilized proteins of infected Sf9 cells were sub-
jected to immunoprecipitation with anti-GFP mAb IgG and then analyzed by SDS-PAGE (7.5%) and immunoblotting. (C) and (D) Western blotting
analysis of GAT1/GFP from uninfected and infected Sf9 cells with anti-GFP pAb or anti-GAT1 pAb. (E) Silver staining of GAT1/GFP from infected Sf9
cells. (F) GNA staining of GAT1/GFP from infected Sf9 cells. The main bands corresponding to the GAT1/GFP fusion protein are indicated with
arrows; Sf9 cells (lane 1), GAT1/GFP infected Sf9 cells (lane 2).
lectin) (Figure 1F), indicating the predominance of the pauci-
mannose structure in insect cells. In contrast, mammalian
N-glycans have terminal sialic acid residues with more antennal
diversity. The band at approximately 250 kDa corresponds to an
oligomeric form or protein aggregate identified through further
characterization.
The two main protein bands after immunoprecipitation and
SDS-PAGE with Coomassie Blue staining (a and b in
Figure 2A) were extracted for protein fingerprinting analysis.
The extracted proteins were processed by trypsin treatment, and
tryptic peptides were analyzed either directly by matrix-assisted
laser desorption/ionization-time-of-flight mass spectrometry
(MALDI–TOF MS) or guanidinated and then analyzed by
MALDI. The labeled peptide peaks (Figure 2B) in the mass
spectrum were identified as either GAT or GFP by matching the
peptides from primary sequence databases with Mascot (http://
www.matrixscience.com/).
The biological function of recombinant proteins of mammalian
origin expressed in insect cells may be altered by different
N-glycan status. We observed that the terminal sialic acid
residues are essential for the GABA uptake activity of GAT1
because they affect the ionic affinity for Na+ and the conforma-
tional change of the GAT1 protein during its uptake process
[12]. After 72 h post-infection, the GABA uptake activity of Sf9
cells was measured to determine whether the GAT1/GFP-fusion
protein was functionally expressed in the baculovirus expres-
sion system. The results showed that infected Sf9 cells
(0.15 pmol/106 cells) have only slightly higher GABA uptake
activity than mock cells (0.1 pmol/106 cells) (Figure S3, Sup-
porting Information File 1). A previous work demonstrated that
co-translational N-glycosylation but not the terminal trimming
of N-glycans is involved in the regulation of the correct mem-
brane glycoprotein folding since the inhibition of N-glycosyla-
tion processing by 1-deoxymannojirimycin (dMM) results in a
mannose-rich type of N-glycan that does not affect either the
protein stability or intracellular trafficking [11]. Therefore, the
correct folding of GAT1/GFP protein in insect cells should not
be affected by the lack of terminal trimming, including the
sialylation of N-glycans. The low GABA uptake activity of
GAT1/GFP fusion protein in insect cells should result from the
terminal mannose structure on the N-glycans, which is consis-
tent with previous findings [12]. Therefore, the GAT1/GFP pro-
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Figure 2: Protein fingerprinting. (A) Coomassie Blue staining of the GAT1/GFP protein from infected Sf9 cells after immunoprecipitation. Bands a and
b (indicated by arrows) were extracted for MALDI–TOF analysis. (B) Mass spectrum of the trypsin digest of band a. The labeled peaks were assigned
to either GAT or GFP.
tein produced in the baculovirus system can be suitable for
further structural analysis with correct folding and more
uniform, less complex N-glycans.
Purification of the GAT1/GFP fusion protein from
insect cells by immunoaffinity chromatography and
size-exclusion (SE) chromatography
A two-step purification procedure for the GAT1/GFP-fusion
protein from Sf9 cells was established. The GAT1/GFP
expressed in Sf9 cells was first isolated with mAb-GFP anti-
body-conjugated affinity chromatography. Subsequently, eluted
fractions containing the GAT1/GFP protein were pooled and
subjected to fast protein liquid chromatography based on SE
(SE-FPLC) with a Superdex 200TM column to obtain purified
homogeneous GAT1/GFP fusion protein.
To isolate the GAT1/GFP protein from the monoclonal anti-
GFP antibody (mAb-GFP)-conjugated affinity column, differ-
ent elution buffers (with different pH values and ionic
strengths) were tested to obtain an effective and appropriate
elution condition for the GAT1/GFP protein without irre-
versibly denaturing or inactivating it. Since no easy and effec-
tive method to control the activity of GAT1 protein during
purification exists, a near-neutral high-salt buffer containing
4 M MgCl2 (pH 6) (Figure 3) was selected to avoid the irre-
versible aggregation of GAT1, which may be caused by high
pH values.
Figure 3: Isolation of the GAT1/GFP fusion protein from Sf9 cells by
mAb-GFP-conjugated affinity column chromatography with analysis of
the eluted fractions from the mAb-GFP-conjugated affinity column with
4 M MgCl2 (pH 6) by SDS-PAGE with silver staining and Western blot-
ting. The arrow denotes the fragment of mAb-GFP. M: standard
marker; CL: cell lysate; FT: flow-through; E1–E8: eluted fractions 1–8.
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Figure 4: Purification of the GAT1/GFP fusion protein from Sf9 cells by SE-FPLC. (A) Elution profile of GAT1/GFP after SE-FPLC on a Superdex
200TM column. (B) The standard linear regression curve of the Superdex 200TM column was generated by plotting the log of the molecular masses of
different calibration proteins against their elution volumes. (C), (D) Silver staining and Western blotting of the SDS-PAGE (7.5%) results of eluted frac-
tions (from 8.8 to 11.8 mL) after SE-FPLC. M: standard marker; C: concentrated sample from immunoaffinity column; 1–10: SE-FPLC fractions from
8.8 to 10.8 mL.
A second purification step with SE-FPLC was performed to
remove the eluted antibodies and other impurities from the
eluates of the immunoaffinity column. The elution profile of the
GAT1/GFP protein is shown in Figure 4A. Compared with the
standard proteins (Figure 4B), two main peaks (1 and 2) appear,
corresponding to Mr of 320 and 162 kDa, respectively. The
fractions (300 μL per fraction) from 8.8 to 11.8 mL after
SE-FPLC were further analyzed by SDS-PAGE (7.5%), fol-
lowed with silver staining and Western blotting (Figure 4C and
4D). The results indicated that peak 1, which should corre-
spond to a tetrameric GAT1/GFP with a molecular weight of
320 kDa, appeared at 8.8–10.6 mL (lanes 2–8). Peak 2 should
correspond to a dimeric form with a molecular weight of
162 kDa, but despite its strong ultraviolet (UV) absorption, it
contained very little GAT1/GFP protein according to the results
of silver staining, Western blot and bicinchoninic acid (BCA)
assay. To prevent the protein from forming oligomers during
purification, different detergents were tested, and n-dodecyl-β-
D-maltoside (DDM, 0.05%) was found to efficiently maintain
the protein in its monomeric form (Figure 5A). The SE-FPLC
elution profile is shown in Figure 5A. Peak 1, which appears at
13.5–14 mL, corresponds to a molecular weight of approxi-
mately 70 kDa, and the overlapping peak 2 (14.7 mL) corre-
sponds to a molecular weight of 45 kDa, which was determined
by comparison with the protein standards (Figure 4B).
Transmission electron microscopy (TEM) analysis
Cryogenic TEM (cryo-TEM) was employed to analyze both
peaks from SE-FPLC to avoid the putative influences of sam-
ple drying and staining salts. The cryofixation by sample nitrifi-
cations is known to preserve the sample in the native state of the
buffer environment and correspondingly the cryo-microscopy
allows a direct visualization of the protein in the fully hydrated
state. After a BCA control, the fraction of peak 2 containing the
larger amount of protein was characterized by cryo-TEM and
showed a very monodisperse distribution of particles
(Figure 5B) with a diameter in the 5–6 nm range, which might
correspond to protein monomers. The peak 1 fraction contains
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only a low amount of the GAT1/GFP protein that exits partly in
an aggregated form (Figure S4, Supporting Information File 1).
Figure 5: Characterization of the GAT1/GFP fusion protein after
SE-FPLC. (A) Elution profile of GAT1/GFP protein after SE-FPLC on a
Superdex 200TM column. (B) Cryo-TEM image of fraction peak 2.
Assumed monomeric GAT1/GFP fusion proteins (M, diameter =
5–6 nm) are indicated with white arrows. The control experiment
revealed no significant population of spherical micelles.
Some noticeable small particles with high contrast were ob-
served. The radius of DDM micelles has been reported to be
approximately 2.6–3.5 nm [32], however, the observed high
contrast is not typical for detergent micelles. As it was not clear
whether the particles could simply be attributed to spherical
micelles control cryo-TEM experiments were performed. Using
a Tris-buffered saline (TBS) solution containing 0.05% DDM
(which is far above the critical micellar concentration (CMC) of
DDM:0.009% or 0.18 mM), no significant population of
micelles could be found. These results suggest that the ob-
served particles most likely correspond to a monodisperse prep-
aration of GAT1/GFP. Several studies have demonstrated that
GAT1 expresses in an oligomeric formation in the plasma
membrane. GAT1 dimers were expressed and examined as a
distinct population of 9 nm freeze-fracture particles in the
plasma membrane of Xenopuslaevis oocytes by freeze-fracture
and electron microscopy [33]. The GAT1 protein monomer was
determined to be the functional unit since each monomer func-
tions independently [33,34]. A similar example is the bacteria
homologue LeuT, which was also crystallized as a dimer [13],
however, each monomer has its own binding pocket, indicating
that the monomers are the functional units. Therefore, a GAT1/
GFP fusion protein monomer could be suitable for further struc-
tural analysis. A yield of approximately 200–300 μg of GAT1/
GFP protein in this fraction was obtained from 400–600 mL of
infected Sf9 cells, quantified by the BCA assay.
Conclusion
The aim of this project was to establish an expression and
purification protocol for the production of high yields of GAT1/
GFP fusion protein. In this work, the baculovirus expression
system was used for the expression of the protein of interest.
The full-length GAT1 protein is composed of twelve highly
hydrophobic TM domains, which promote strong aggregation
behavior of the protein, if it is isolated from the membrane. The
presented protocol allows for the efficient production of the
GAT1/GFP fusion protein in its monomeric form. We demon-
strated that pure monomeric GAT1/GFP protein can be ob-
tained with yields of approximately 200–300 μg from
400–600 mL of infected Sf9 cell culture. Moreover, consid-
ering the effect of N-linked glycans on the activity of the GAT1
protein, the glycol-engineered insect cells coupled with the
baculovirus system may be further applied to produce a GAT1/
GFP protein with complex, terminally sialylated N-glycans.
Further structural analysis of the GAT1/GFP fusion protein is
possible using crystallography, thereby improving our under-
standing of the three-dimensional structure of the GAT1 pro-
tein.
Experimental
Immunoprecipitation and Western blotting
The immunoprecipitation and Western blotting procedures were
similar to those described previously [12]. Briefly, the GAT1/
GFP protein was solubilized at 4 °C or on ice. After infection,
insect cells were collected, washed once with phosphate-
buffered saline (PBS), and resuspended in TBS buffer (50 mM
Tris, pH 7.3, 150 mM NaCl). The suspended cells were soni-
cated at 4 °C for 15 min and cell debris was removed by
centrifugation at 6,000g for 10 min at 4 °C. A turbid super-
natant solution containing the cell membranes was obtained.
After centrifugation at 100,000g at 4 °C for 30 min, the crude
membrane fractions were solubilized in TBS containing 1%
DDM and stirred for at least 4 h at 4 °C. The lysate was
centrifuged at 18,000g at 4 °C for 1 h. Total protein concentra-
tions of the supernatant were measured with BCA™ Protein
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Assay Kit (Thermo). Quantified aliquots of the supernatants
were incubated with protein-G-Sepharose-bound anti-GFP IgG
for 12 h at 4 °C. After intensive washing, the immunoprecipi-
tates were eluted by boiling for 3 min in SDS sample buffer.
The supernatant aliquots were divided in half and then subject-
ed to SDS-PAGE; the separated proteins were transferred to a
nitrocellulose membrane (Millipore) by Western blotting. One
blot membrane was used for the immunostaining of the GAT1
protein with the anti-GAT1 or anti-GFP polyclonal antiserum.
Subsequently, the blots were incubated with horseradish peroxi-
dase-conjugated anti-rabbit antibody (IgG) (Dako Cytomation)
and then visualized using amino ethylcarbazole (AEC) and sub-
strate buffer (Calbiochem).
Flow cytometry and fluorescence microscopy
Sf9 cells were observed after 3-day infection by flow cytometry
and fluorescence microscopy to determine the cell surface
expression of the GAT1/GFP fusion proteins.
MALDI mass fingerprinting
Using MALDI–TOF MS, protein fragments with blocked
N-termini or that are available in limited concentrations can be
easily analyzed. The MALDI mass fingerprinting was per-
formed by Dr. Chris Weise (Free University Berlin, Germany)
with a Bruker-Biflex Reflex Mass spectrometer (Bruker
Daltonics) in the reflector-mode with alpha-cyano-4-hydroxy-
cinnamic acid as matrix. Ionization was enhanced with the
337 nm-ray of a nitrogen laser. The peptide masses were deter-
mined by calibration with the PAC peptide calibrant standard.
All solutions and buffers used were prepared with sterile pure
high-performance LC (HPLC)-grade water (Milli-Q® Water
filter apparatus, Millipore) in order to avoid contaminations.
Evaluation and identification of the mass spectra were per-
formed using the Internet search software Mascot [35].
Purification of GAT1 and protein identification
Isolation of GAT1/GFP by the immunoaffinity
column
The immunoaffinity column was prepared as followed: 200 µL
Affi-gel 10 protein-A-sepharose (Amersham Pharmacia,
Sweden) were loaded on a 10 mL disposable chromatography
column and washed twice with 1 mL ice cold double-distilled
(dd)H2O. Approximately 6–8 mg of purified antibody in 0.1 M
MOPS buffer, pH 7.5, was added to the resin, and the columns
were incubated overnight at 4 °C to allow covalent binding.
Subsequently, unbound antibodies were collected as the flow-
through, and the sepharose column was washed once with 1 mL
of 1 M ethanolamine (pH 8.0). Blocking of the sepharose was
performed with 3 mL of 1 M ethanolamine (pH 8.0) for 2 h at
room temperature (rt). Finally, the antibody-coupled sepharose
was washed three times with 15 mM sodium phosphate buffer
(pH 8.0). Prior to subsequent use of the affinity columns, 1 mL
of PBS with 0.02% NaN3 was added to the sepharose, which
was then stored at 4 °C.
Cells were lysed in solubilization buffer (10 mM Tris, pH 7.8,
150 mM NaCl, 1 mM CaCl2, 2% DDM) containing 1 mM
dithiothreitol (DTT) and protease inhibitor cocktail (1:500)
(Merck). After a 4 × 30 s sonication step, the cells were incubat-
ed overnight at 4 °C with agitation. The solubilized protein was
fractionated by 45 min of centrifugation at 18,000 rpm.
The cell lysate was added directly to the immunoaffinity chro-
matography resin. Proteins were coupled on the column by
overnight agitation at 4 °C. Unbound proteins were collected as
flow-through and the resin was washed three times with radio
immunoprecipitation assay buffer (RIPA) and twice with
prewash. The elution of the GAT1/GFP was achieved with
8 × 250 µL of elution buffer (50 mM diethylamine, pH 11.4).
The eluates were neutralized immediately by adding 100 µL of
0.5 M NaH2PO4 to each tube in which the eluates were
collected.
FPLC based on size exclusion (SE-FPLC)
The immunopurif ied GAT1/GFP isolated from the
immunoaffinity column was concentrated to 250–300 μL with a
Vivaspin column (Vivasciences) at 4 °C and 3,000g. The
concentrate was further purified by SE-FPLC on a Superdex
200 column (GE Healthcare) that had been equilibrated with
equilibrium buffer (10 mM Tris, pH 7.8, 150 mM NaCl, and
0.05% DDM). Elution of the protein was performed with equi-
librium buffer at a flow rate of 0.3 mL/min. The molecular
weight of the obtained protein was determined based on the




Sample droplets (5 μL) of the sample were placed onto
hydrophilized (glow discharged for 60 s at 8 W in a BALTEC
MED 020 device (Baltec, Liechtenstein) carbon-covered micro-
scopical copper grids (400 mesh), and the supernatant fluid was
removed with a filter paper to create an ultrathin layer of the
sample. A droplet of contrasting material (1% uranyl acetate,
2% phosphotungstic acid or 2% ammonium molybdate in the
presence of 0.1% trehalose) was added, blotted again and air-
dried. Imaging was performed using a Tecnai F20 FEG (FEI
Company, Oregon) at an accelerating voltage of 160 kV under
low-dose conditions. Micrographs were recorded according to
the low-dose protocol of the microscope at a primary magnifi-
cation of 62,000×. The defocus value was chosen to correspond
to the first zero of the contrast transfer function (CTF) at ≈15 Å.
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Cryo-TEM
Similarly as described previously [36], vitrified samples were
transferred into a Tecnai F20 FEG using a Gatan cryo-holder
and -stage (Model 626). Samples were constantly cooled by
LN2 during imaging to maintain a sample temperature of
T = 93 K. Imaging was performed at an accelerating voltage of
160 kV with a defocus value of 600 nm, which corresponds to
the first zero of the CTF at 13 Å (Cs = 2.0 mm). Micrographs
were recorded according to the low-dose protocol of the micro-
scope at a primary magnification of 62, 000×.
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